cbdMD (YCBD) Short term Debt (2016 - 2024)
cbdMD (YCBD) posted Short term Debt of $362021.0 for Q4 2024, down 69.09% sequentially from $1.2 million in Q3 2024.
cbdMD (YCBD) Short term Debt (2016 - 2024) Analysis & Trends
cbdMD has reported Short term Debt for 4 years, with the latest figure at $362021.0 in Q4 2024.
- Quarterly Short term Debt changed N/A year-over-year to $362021.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $362021.0 (changed N/A YoY) and the FY2024 annual result came in at $1.2 million, changed N/A from the prior year.
- Short term Debt fell to $362021.0 in Q4 2024 per YCBD's latest filing, from $1.2 million in the prior quarter.
- Over five years, Short term Debt peaked at $1.2 million in Q3 2024 and troughed at $362021.0 in Q4 2024.
- A 3-year average of $870911.6 and a median of $939826.0 in 2020 frame the typical range for Short term Debt.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | cbdMD | 5.41 Mn | 3.29 Mn | 3.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 362,021.00 |
| Sep 30, 2024 | 1.17 Mn |
| Mar 31, 2021 | 1.03 Mn |
| Dec 31, 2020 | 939,826.00 |
| Sep 30, 2020 | 854,000.00 |
| Sep 30, 2016 | 797,547.00 |